# CYCLOMETHICONE (cyclomethicone) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/cyclomethicone
- **Standard INCI**: `CYCLOMETHICONE`
- **KR MFDS Standard Name**: `사이클로메티콘`
- **CAS No.**: `69430-24-6`
- **EC / EINECS No.**: `209-136-7`
- **Origin**: `synthetic`
- **Functions**: 모발컨디셔닝제, 용제, 에모리엔트
- **Molecular Formula / MW**: `—` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 사이클로메티콘 |
| KR (Former Names) | 사이클로메치콘 |
| EU (CosIng 1223/2009) | CYCLOMETHICONE |
| US (PCPC / MoCRA INCI) | CYCLOMETHICONE |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 环聚二甲基硅氧烷 |
| JP (JCIA / MHLW QD) | CYCLOMETHICONE  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `banned`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `3026`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`

- **EU** [banned]: — —  (Regulation (EC) No 1223/2009 Annex II — via CosIng (EU Commission))

## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- Listed within general cosmetic GMP safety thresholds.

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4 – 8
- **Max Process Temp**: ≤ 50°C
- **Synergy Pairings**: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL
- **Incompatibilities**: Verify phase compatibility under extreme pH or high electrolyte loads

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: CYCLOMETHICONE | CAS No.: 69430-24-6 | EC No.: 209-136-7
  - Origin: SYNTHETIC | Functions: , , 
  - Physicochemical Profile: Formula      | MW /(Polymer/Complex) | /   | Ionic Nature: non-ionic | CosIng/MFDS 
  - Official Regional Label Names: US [CYCLOMETHICONE] · EU [CYCLOMETHICONE] · CN [环聚二甲基硅氧烷] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Cyclomethicone is a generic name for a mixture of cyclic dimethyl polysiloxane compounds that conform to the formula, where n has a value between 4 and 6. Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , ,  performance and structural formulation stability.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NONE | EU: BANNED | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 3026 (环聚二甲基硅氧烷))
  - [EU / COMPOSITION / banned]: 
  - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - [aqueous_serum] Typical range: 5.0 ~ 54.0% (Median 27.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=9, ELEMENTIS 9)) — Aqueous serum, toner & hydrogel matrix formulation component
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Water Phase or Cool-down Phase (< 45°C)
  - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM
  - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads
  - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: CYCLOMETHICONE
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 22943314 (2012, BMC Dermatol): Effectiveness of isopropyl myristate/cyclomethicone D5 solution of removing cuticular hydrocarbons from human head lice 
  - PMID 22247236 (2011, Int J Toxicol): Safety assessment of cyclomethicone, cyclotetrasiloxane, cyclopentasiloxane, cyclohexasiloxane, and cycloheptasiloxane
  - PMID 40988838 (2025, Cureus): Taming the Rash: A Dermatological Case Report on Effective Treatments for Refractory Folliculitis

## 6. Linked PubMed Literature
- [PMID: 22943314] Effectiveness of isopropyl myristate/cyclomethicone D5 solution of removing cuticular hydrocarbons from human head lice (Pediculus humanus capitis) — *BMC Dermatol* (2012)
- [PMID: 22247236] Safety assessment of cyclomethicone, cyclotetrasiloxane, cyclopentasiloxane, cyclohexasiloxane, and cycloheptasiloxane — *Int J Toxicol* (2011)
- [PMID: 40988838] Taming the Rash: A Dermatological Case Report on Effective Treatments for Refractory Folliculitis — *Cureus* (2025)
- [PMID: 35040730] Preparation of topical bimatoprost with enhanced skin infiltration and in vivo hair regrowth efficacy in androgenic alopecia — *Drug Deliv* (2022)
- [PMID: 33925457] Preparation of Topical Itraconazole with Enhanced Skin/Nail Permeability and In Vivo Antifungal Efficacy against Superficial Mycosis — *Pharmaceutics* (2021)
- [PMID: 31738083] Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis — *Drug Deliv* (2019)
- [PMID: 27601420] Exposure to cyclic volatile methylsiloxanes (cVMS) causes anchorage-independent growth and reduction of BRCA1 in non-transformed human breast epithelial cells — *J Appl Toxicol* (2017)
- [PMID: 26107421] Particles at Oil-Air Surfaces: Powdered Oil, Liquid Oil Marbles, and Oil Foam — *ACS Appl Mater Interfaces* (2015)
- [PMID: 24585370] Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides — *J Pharm Sci* (2014)
- [PMID: 24184663] Concentrations of cyclic volatile methylsiloxanes in European cosmetics and personal care products: prerequisite for human and environmental exposure assessment — *Environ Int* (2014)
- [PMID: 24004959] Tocopheryl acetate 20% spray for elimination of head louse infestation: a randomised controlled trial comparing with 1% permethrin creme rinse — *BMC Pharmacol Toxicol* (2013)
- [PMID: 23710417] Pilot study to evaluate the effect of topical dimethicone on clinical signs and skin barrier function in dogs with naturally occurring atopic dermatitis — *Vet Med Int* (2013)